Recent Updates
Recently added Catalysts

Unity Biotechnology, Inc.

UBXFDA catalysts, PDUFA dates & pipeline intelligence
$0.2
▼ -0.08 · -29.14%

Last traded Jul 8, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full UBX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.2052W HIGH $3.10
Volume
3.85 M
Value Traded
927.66 K
Short % Float
3.65%
Days to Cover
1.7
-39.73%Week
-71%1 Month
-78.01%3 Month
-87.8%6 Month
-99.75%5 Year
-99.89%All Time

Cash Data

Unlock UBX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.44 M
EPS (TTM)
-1.63
P/E Ratio
-
Ent. Value
9.09 M
Total Shares
17.21 M
Float Shares
15.68 M
Insiders
8.92%
Institutions
11.46%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every UBX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

UBX Catalyst Timeline

Dated clinical, regulatory and corporate events for Unity Biotechnology, Inc.

Unlock the full UBX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How UBX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-05-07UBX1325 (senolytic candidate) Phase 2b data readout Phase 2b
Unlock all UBX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Showing 3 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
UBX1325 50 μL Small moleculeCompletedNCT05275205Neovascular Age-related Macular DegenerationPhase 2 COMPLETED 51Jul 25, 2023
foselutoclax Small moleculeCompletedNCT06011798Diabetic Macular EdemaPhase 2 COMPLETED 52Apr 8, 2025
UBX1325 Small moleculeCompletedNCT04537884Diabetic Macular EdemaPhase 2 COMPLETED 84Jan 25, 2022
Unlock the UBX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every UBX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
UBX1325 diabetic macular edemaPhase 2b2025-05-05statistically non-inferior to aflibercept; superior vision gains in a pre-specified subgroup of patients entering the study with CST <400 microns (60% of enrolled patients)Read MoreUNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate UpdatesRead More
Scroll for more · summaries link to the source press release
Unlock every UBX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock UBX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Nguyen Alexander HieuOfficer (CLO and Head of Ops)Sell -17,852 48,753 held$1.03 04/02/2025
Unlock the full UBX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in UBX

Fund % of Portfolio Current MV Shares Owned Activity
PARKMAN HEALTHCARE PARTNERS LLC 0 % 117.13 K 42.75 K -89.42% ( -361.34 K)
Unlock every fund holding UBX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in UBX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see UBX ownership
Insider and institutional ownership, quarter by quarter.

UBX Short Interest

Shares sold short, counted twice a month.

3.65%
Short % of Float
of tradable shares sold short
551.6K
Shares Sold Short
-3.6% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
317.3K
Avg Daily Volume
the average used for days to cover
Unlock UBX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock UBX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live UBX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock UBX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How UBX ranks across every disease it competes in

Competitive Position is a premium feature
See how UBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

UBX News

About Unity Biotechnology, Inc.

Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next UBX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime